Home › Compare › CAJTF vs MRK

CAJTF vs MRK: Dividend Comparison 2026

CAJTF yields 1250.00% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CAJTF wins by $135327077.56M in total portfolio value
10 years
CAJTF
CAJTF
● Live price
1250.00%
Share price
$0.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$135327077.59M
Annual income
$116,926,161,071,848.38
Full CAJTF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — CAJTF vs MRK

📍 CAJTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCAJTFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CAJTF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CAJTF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CAJTF
Annual income on $10K today (after 15% tax)
$106,250.00/yr
After 10yr DRIP, annual income (after tax)
$99,387,236,911,071.11/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, CAJTF beats the other by $99,387,236,910,263.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CAJTF + MRK for your $10,000?

CAJTF: 50%MRK: 50%
100% MRK50/50100% CAJTF
Portfolio after 10yr
$67663538.81M
Annual income
$58,463,080,536,399.34/yr
Blended yield
86.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CAJTF
No analyst data
Altman Z
-0.9
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CAJTF buys
0
MRK buys
0
No recent congressional trades found for CAJTF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCAJTFMRK
Forward yield1250.00% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$135327077.59M ✓$30.7K
Annual income after 10y$116,926,161,071,848.38 ✓$950.29
Total dividends collected$133960810.96M ✓$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CAJTF vs MRK ($10,000, DRIP)

YearCAJTF PortfolioCAJTF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$135,700$125,000.00$11,192$351.54+$124.5K → CAJTF
2$1,730,479$1,585,280.37$12,524$392.70+$1.72M → CAJTF
3$20,744,959$18,893,346.29$14,015$438.65+$20.73M → CAJTF
4$233,872,934$211,675,827.14$15,682$489.96+$233.86M → CAJTF
5$2,480,500,804$2,230,256,765.05$17,547$547.23+$2480.48M → CAJTF
6$24,761,170,753$22,107,034,892.35$19,632$611.16+$24761.15M → CAJTF
7$232,737,122,500$206,242,669,794.36$21,963$682.53+$232737.10M → CAJTF
8$2,060,741,008,119$1,811,712,287,044.72$24,571$762.18+$2060740.98M → CAJTF
9$17,197,118,239,637$14,992,125,360,949.39$27,486$851.08+$17197118.21M → CAJTF
10$135,327,077,588,260$116,926,161,071,848.38$30,745$950.29+$135327077.56M → CAJTF

CAJTF vs MRK: Complete Analysis 2026

CAJTF — Stock

Canada Jetlines Operations Ltd focuses on operating as a leisure focused carrier utilizing a fleet of aircraft. The company is based in Vancouver, Canada.

Full CAJTF Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this CAJTF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CAJTF vs SCHDCAJTF vs JEPICAJTF vs OCAJTF vs KOCAJTF vs MAINCAJTF vs JNJCAJTF vs ABBVCAJTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.